Marina Chiara Garassino to Aged, 80 and over
This is a "connection" page, showing publications Marina Chiara Garassino has written about Aged, 80 and over.
Connection Strength
1.196
-
Poziotinib for EGFR and HER2 exon 20 insertion mutation in advanced NSCLC: Results from the expanded access program. Eur J Cancer. 2021 05; 149:235-248.
Score: 0.093
-
Patient-reported outcomes following pembrolizumab or placebo plus pemetrexed and platinum in patients with previously untreated, metastatic, non-squamous non-small-cell lung cancer (KEYNOTE-189): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 2020 03; 21(3):387-397.
Score: 0.086
-
Nivolumab in never-smokers with advanced squamous non-small cell lung cancer: Results from the Italian cohort of an expanded access program. Tumour Biol. 2018 Nov; 40(11):1010428318815047.
Score: 0.079
-
Italian Nivolumab Expanded Access Program in Nonsquamous Non-Small Cell Lung Cancer Patients: Results in Never-Smokers and EGFR-Mutant Patients. J Thorac Oncol. 2018 08; 13(8):1146-1155.
Score: 0.076
-
Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer. N Engl J Med. 2018 May 31; 378(22):2078-2092.
Score: 0.076
-
Small-Cell Lung Cancer: Clinical Management and Unmet Needs New Perspectives for an Old Problem. Curr Drug Targets. 2017; 18(3):341-362.
Score: 0.069
-
Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial. Lancet Oncol. 2013 Sep; 14(10):981-8.
Score: 0.055
-
Randomised phase II trial (NCT00637975) evaluating activity and toxicity of two different escalating strategies for pregabalin and oxycodone combination therapy for neuropathic pain in cancer patients. PLoS One. 2013; 8(4):e59981.
Score: 0.054
-
Poziotinib in Non-Small-Cell Lung Cancer Harboring HER2 Exon 20 Insertion Mutations After Prior Therapies: ZENITH20-2 Trial. J Clin Oncol. 2022 03 01; 40(7):710-718.
Score: 0.024
-
Gemcitabine with or without ramucirumab as second-line treatment for malignant pleural mesothelioma (RAMES): a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Oncol. 2021 10; 22(10):1438-1447.
Score: 0.024
-
Immune-Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer With Uncommon Histology. Clin Lung Cancer. 2022 01; 23(1):e17-e28.
Score: 0.024
-
Differential influence of antibiotic therapy and other medications on oncological outcomes of patients with non-small cell lung cancer treated with first-line pembrolizumab versus cytotoxic chemotherapy. J Immunother Cancer. 2021 04; 9(4).
Score: 0.023
-
Five-Year Outcomes From the Randomized, Phase III Trials CheckMate 017 and 057: Nivolumab Versus Docetaxel in Previously Treated Non-Small-Cell Lung Cancer. J Clin Oncol. 2021 03 01; 39(7):723-733.
Score: 0.023
-
Pembrolizumab plus chemotherapy versus chemotherapy alone in patients with advanced non-small cell lung cancer without tumor PD-L1 expression: A pooled analysis of 3 randomized controlled trials. Cancer. 2020 11 15; 126(22):4867-4877.
Score: 0.022
-
Impact of performance status on non-small-cell lung cancer patients with a PD-L1 tumour proportion score =50% treated with front-line pembrolizumab. Acta Oncol. 2020 Sep; 59(9):1058-1063.
Score: 0.022
-
Tepotinib in Non-Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations. N Engl J Med. 2020 09 03; 383(10):931-943.
Score: 0.022
-
Updated Analysis From KEYNOTE-189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non-Small-Cell Lung Cancer. J Clin Oncol. 2020 05 10; 38(14):1505-1517.
Score: 0.022
-
Relationship Between Programmed Death Receptor-Ligand 1 Expression and Response to Checkpoint Inhibitor Immunotherapy in Pulmonary Sarcomatoid Carcinoma: A Pooled Analysis. Clin Lung Cancer. 2020 09; 21(5):e456-e463.
Score: 0.022
-
DiM: Prognostic Score for Second- or Further-line Immunotherapy in Advanced Non-Small-Cell Lung Cancer: An External Validation. Clin Lung Cancer. 2020 09; 21(5):e337-e348.
Score: 0.022
-
Efficacy and safety of immunotherapy in elderly patients with non-small cell lung cancer. Lung Cancer. 2019 11; 137:38-42.
Score: 0.021
-
Characterization of patients with metastatic non-small-cell lung cancer obtaining long-term benefit from immunotherapy. Future Oncol. 2019 Aug; 15(23):2743-2757.
Score: 0.021
-
Association between antibiotic-immunotherapy exposure ratio and outcome in metastatic non small cell lung cancer. Lung Cancer. 2019 06; 132:72-78.
Score: 0.020
-
Oral maintenance metronomic vinorelbine versus best supportive care in advanced non-small-cell lung cancer after platinum-based chemotherapy: The MA.NI.LA. multicenter, randomized, controlled, phase II trial. Lung Cancer. 2019 06; 132:17-23.
Score: 0.020
-
Nivolumab and brain metastases in patients with advanced non-squamous non-small cell lung cancer. Lung Cancer. 2019 03; 129:35-40.
Score: 0.020
-
Randomised phase 2 study of pembrolizumab plus CC-486 versus pembrolizumab plus placebo in patients with previously treated advanced non-small cell lung cancer. Eur J Cancer. 2019 02; 108:120-128.
Score: 0.020
-
CNS Efficacy of Osimertinib in Patients With T790M-Positive Advanced Non-Small-Cell Lung Cancer: Data From a Randomized Phase III Trial (AURA3). J Clin Oncol. 2018 09 10; 36(26):2702-2709.
Score: 0.019
-
RELEVENT Trial: Phase II Trial of Ramucirumab, Carboplatin, and Paclitaxel in Previously Untreated Thymic Carcinoma/B3 Thymoma With Area of Carcinoma. Clin Lung Cancer. 2018 09; 19(5):e811-e814.
Score: 0.019
-
Uncommon mutations in epidermal growth factor receptor and response to first and second generation tyrosine kinase inhibitors: A case series and literature review. Lung Cancer. 2018 01; 115:135-142.
Score: 0.019
-
Phase II Trial of Atezolizumab As First-Line or Subsequent Therapy for Patients With Programmed Death-Ligand 1-Selected Advanced Non-Small-Cell Lung Cancer (BIRCH). J Clin Oncol. 2017 Aug 20; 35(24):2781-2789.
Score: 0.018
-
Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer. N Engl J Med. 2017 02 16; 376(7):629-640.
Score: 0.017
-
ALK gene copy number gains in non-small-cell lung cancer: prognostic impact and clinico-pathological correlations. Respir Res. 2016 08 25; 17(1):105.
Score: 0.017
-
Deciphering intra-tumor heterogeneity of lung adenocarcinoma confirms that dominant, branching, and private gene mutations occur within individual tumor nodules. Virchows Arch. 2016 Jun; 468(6):651-62.
Score: 0.016
-
Doing more with less: fluorescence in situ hybridization and gene sequencing assays can be reliably performed on archival stained tumor tissue sections. Virchows Arch. 2016 Apr; 468(4):451-61.
Score: 0.016
-
Dissecting Pulmonary Large-Cell Carcinoma by Targeted Next Generation Sequencing of Several Cancer Genes Pushes Genotypic-Phenotypic Correlations to Emerge. J Thorac Oncol. 2015 Nov; 10(11):1560-9.
Score: 0.016
-
Does surgery improve survival of patients with malignant pleural mesothelioma?: a multicenter retrospective analysis of 1365 consecutive patients. J Thorac Oncol. 2014 Mar; 9(3):390-6.
Score: 0.014
-
Does immunohistochemistry affect response to therapy and survival of inoperable non-small cell lung carcinoma patients? A survey of 145 stage III-IV consecutive cases. Int J Surg Pathol. 2014 Apr; 22(2):136-48.
Score: 0.014
-
?Np63 (p40) distribution inside lung cancer: a driver biomarker approach to tumor characterization. Int J Surg Pathol. 2013 Jun; 21(3):229-39.
Score: 0.013
-
Multiparametric molecular characterization of pulmonary sarcomatoid carcinoma reveals a nonrandom amplification of anaplastic lymphoma kinase (ALK) gene. Lung Cancer. 2012 Sep; 77(3):507-14.
Score: 0.013
-
Second-line chemotherapy in malignant pleural mesothelioma: results of a retrospective multicenter survey. Lung Cancer. 2012 Mar; 75(3):360-7.
Score: 0.012
-
A mono-institutional prospective study on the effectiveness of a specialist psychotherapeutic intervention (POI) started at the diagnosis of cancer. Support Care Cancer. 2012 Mar; 20(3):475-81.
Score: 0.011